Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
85 hedge funds and large institutions have $52.2M invested in Sorrento Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 11 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 18
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
11% more call options, than puts
Call options by funds: $901K | Put options by funds: $813K
2% more funds holding
Funds holding: 83 → 85 (+2)
31% less capital invested
Capital invested by funds: $75.3M → $52.2M (-$23M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$775K |
| 2 |
BlackRock
New York
|
+$676K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$338K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$239K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.58M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.74M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.77M |
| 4 |
WCM
Wildcat Capital Management
New York
|
-$1.11M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$301K |
SRNE Hedge Fund Activity: Q3 2019 in Review
85 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2019, worth a combined $52.2M — down 31% from $75.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SRNE positions and 11 closed out — a net gain of 2 holders — while 31 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $775K. The largest seller was Deerfield Management, exiting entirely with an estimated $5.58M sold.
- 85 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2019, up from 83 in Q2 2019.
- Funds reported $52.2M of Sorrento Therapeutics, Inc. stock for Q3 2019, down 31% quarter-over-quarter.
- 13 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2019 and 11 closed out, a net change of +2 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2019 was Vanguard Group, an estimated $775K added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2019 was Deerfield Management, an estimated $5.58M sold.
Based on aggregated 13F filings for Q3 2019.